MEHRDAD BANDEGI

Mr. MEHRDAD BANDEGI

orcid
Biomedical Engineering Department, University of Houston, US...

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MMMegan Mendieta
Megan Mendieta
MEHRDAD BANDEGIMEHRDAD BANDEGI
MEHRDAD BANDEGI
EBEzgi Biltekin
Ezgi Biltekin
Metin AkayMetin Akay
Metin Akay
BOBulent ozpolat
Bulent ozpolat
Metin AkayMetin Akay
Metin Akay
Glioblastoma Multiforme (GBM) is one of the most common brain tumors and is associated with aggressive tumor characteristics and extremely poor patient survival. The median survival time for GBM patients is around 12–15 months. Temozolomide (TMZ) is a key chemotherapeutic drug used in the treatment of GBM. However, at least 50% of GBM patients do not respond to TMZ, necessitating the identification of novel therapeutic strategies sensitizing patients to TMZ. In this study, we aimed to investigate the effects of two different tumor suppressor microRNAs (miR-329 and miR-449b) on cell proliferation and migration of GBM cells, and their potential for sensitizing GBM cells to TMZ. Our findings show that MiR-329/449b treatments suppressed spheroid formation and migration of GBM (LN229 and U87) cells. When miR treatments were combined with Temozolomide (TMZ), we also observed that they synergistically enhanced the suppressive effects of TMZ and inhibited the activity of clinically significant NF-KB and Src/FAK signaling pathways, making the combination therapy a viable option to treat GBM, with greater impact on patient survival.

30 March 2026 in IEEE Open Journal of Engineering in Medicine and Biology
Verified
Journal Article
Open access
MEHRDAD BANDEGIMEHRDAD BANDEGI
MEHRDAD BANDEGI
EBEzgi Biltekin
Ezgi Biltekin
Metin AkayMetin Akay
Metin Akay
BOBulent Ozpolat
Bulent Ozpolat
Metin AkayMetin Akay
Metin Akay
Colorectal cancer (CRC) ranks third in incidence among all malignancies and is highly lethal in advanced stages. Combination chemotherapy regimens based on 5-fluorouracil (5-FU) remain the mainstay of colorectal cancer treatment alongside surgical resection. Even though new treatment modalities are emerging, many are either ineffective against KRAS-mutant tumors or prone to therapy resistance. Therefore, there is a critical need for new targeted therapies that may overcome the KRAS-driven chemoresistance and enhance the effect of chemotherapy. MicroRNAs can modulate several oncogenic pathways at once and can strengthen chemotherapy. In this study, we identified miR-873 as a potential chemosensitizer that modulates KRAS/MAPK signaling in CRC. We found that KRAS is overexpressed in metastatic versus primary tissues and in a large CRC patient cohort (n = 1,061), high KRAS expression was associated with worse overall survival (HR = 1.27; 95% CI, 1.04–1.56; log-rank p = 0.018). In vitro inhibition of KRAS by siRNA reduced clonogenic growth (HCT116, p = 0.0023; RKO, p = 0.0018) and invasion (p ≤ 0.0001). In silico prediction (TargetScan/miRWalk) analyses showed a conserved binding site between miR-873 and KRAS 3′UTR. Consistent with this prediction, miR-873 mimic transfection reduced KRAS protein expression and phenocopied KRAS knockdown by suppressing colony formation (p ≤ 0.0021) and invasion (p ≤ 0.0001) in KRAS-mutant HCT116 and KRAS-wild-type RKO cells. Dose-matrix screening and SynergyFinder+ analysis revealed synergistic inhibition of spheroid viability with miR-873 + 5-FU, including a low-dose pair (25 nM miR-873 + 12.5 μM 5-FU) showing positive synergy across ZIP/HSA/Bliss/Loewe models. In a poly(ethylene glycol)diacrylate(PEGDA) microwell 3D platform that generates uniform, size-controlled CRC spheroids, this combination produced the strongest suppression of spheroid expansion (day-5/day-3 area: HCT116, 0.61 ± 0.18 vs control, 2.08 ± 0.49; RKO, 0.66 ± 0.04 vs control, 2.08 ± 0.31) and reduced the live-cell fraction to ∼41% in both lines. Moreover, western blot analysis showed decreased KRAS and MAPK pathway activity (reduced p-ERK and context-dependent p-MEK), reduced Cyclin D1, and increased apoptotic readouts (cleaved PARP and a Bax/Bcl-2 shift). Together, these results position miR-873 treatment as a potential targeting approach to suppress KRAS/MAPK signaling and sensitize CRC to 5-FU and validate our PEGDA microwell 3D platform as a practical, translational testbed for miRNA–chemotherapy combinations.

10 March 2026 in Metabolism Open
Verified
Journal Article
Open access
Sina Salem AhimSina Salem Ahim
Sina Salem Ahim
MEHRDAD BANDEGIMEHRDAD BANDEGI
MEHRDAD BANDEGI
EGErfan Ghanbarzadeh
Erfan Ghanbarzadeh
Roozbeh Heidarzadeh-PilehroodRoozbeh Heidarzadeh-Pilehrood
Roozbeh Heidarzadeh-Pilehrood
Evidence supporting the involvement of non-coding RNAs (ncRNAs) in neuronal plasticity and susceptibility has been fragmented across different diseases and ncRNA subtypes. We propose an evidence-tiered, axis-based framework integrating microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) across major neurodegenerative disorders. We have focused on studies that have attempted to establish links between ncRNAs and disease pathogenesis through functional perturbation, validation, and/or rescue in relevant disease models. To facilitate cross-disease comparison, we have categorized these studies along four axes of proteostasis/protein aggregation, neuroinflammation, synaptic/circuit dysfunction, and mitochondrial/autophagy dysfunction. Overall, these ncRNAs have been reported to function as modulators and potential indicators of bioenergetic stress, influencing glial cell function, neuronal survival, metabolic vulnerability, and network plasticity. We have highlighted common regulatory modules, including the role of miRNAs in modulating autophagy and inflammatory-metabolic coupling, lncRNAs in regulating amyloid/synuclein-related processes, and circRNA-mediated miRNA/RBP modules in regulating processes involving mitochondria, while also pointing out discrepancies. We have also discussed the possibility of ncRNA panels and therapeutics, facilitated by advances in delivery strategies, for the discovery of biomarkers and drug targets, while also pointing out some of the challenges that need to be addressed, including heterogeneity of evidence, cell-type specificity, blood–brain barrier constraints, and off-target effects.

Verified
Journal Article
Open access
PDF file
MEHRDAD BANDEGIMEHRDAD BANDEGI
MEHRDAD BANDEGI
EBEzgi Biltekin
Ezgi Biltekin
Metin AkayMetin Akay
Metin Akay
Metin AkayMetin Akay
Metin Akay
Colorectal cancer (CRC) is a major cause of cancer-related mortality among adults younger than 50 years of age, and many tumors show incomplete response or develop resistance to 5-fluorouracil (5-FU)-based chemotherapy. Therefore, new therapeutic approaches that improve CRC sensitivity to existing chemotherapeutic agents are needed. KRAS-associated signaling contributes to CRC growth, metabolic adaptation and treatment resistance. In this study, we investigated whether sulfasalazine (SSZ), a U.S. Food and Drug Administration (FDA)-approved anti-inflammatory drug, could enhance the response of CRC cells to 5-FU and modulate KRAS/mitogen-activated protein kinase (MAPK)-associated signaling. Public dataset analysis using cBioPortal, Kaplan–Meier Plotter and DepMap showed that KRAS is commonly altered in CRC. The analysis also showed that higher KRAS expression was associated with shorter overall survival in 1061 CRC patients, while CRC cell-line models demonstrated KRAS dependency. In 2D cultures, both KRAS-mutant HCT116 and KRAS-wild-type RKO cells showed lower cell viability, reduced colony formation and decreased KRAS expression after SSZ treatment. In 3D cultures, exposure to SSZ reduced early spheroid formation, both as a single treatment and when combined with 5-FU. In established spheroids, SSZ-containing treatments affected cell viability, spheroid growth and morphology, with the most noticeable suppressive effect observed in RKO aggregates. SynergyFinder+ dose-matrix analysis identified dose ranges where SSZ and 5-FU showed additive-to-synergistic effects, leading us to select 600 μM SSZ with 25 μM 5-FU for further validation. Western blot results from PEGDA microwell-derived 3D spheroids showed that SSZ + 5-FU treatment reduced KRAS expression and affected KRAS/MAPK-related signaling. This effect was more pronounced in RKO cells, where downstream pathway suppression was stronger. The combination treatment also increased apoptosis-associated PARP cleavage. At the same time, it reduced Cyclin D1 and GPX4 protein levels and changed the expression of stemness-related markers, including ALDH1A3, CD44, and CD133. Together, these results support SSZ as a candidate repurposed adjuvant that may improve the response to 5-FU in CRC spheroid models and support the use of PEGDA microwell-based 3D platforms for testing combination therapy approaches.